CN101415827A - 产生抗原特异性效应t细胞的方法 - Google Patents

产生抗原特异性效应t细胞的方法 Download PDF

Info

Publication number
CN101415827A
CN101415827A CNA2006800510949A CN200680051094A CN101415827A CN 101415827 A CN101415827 A CN 101415827A CN A2006800510949 A CNA2006800510949 A CN A2006800510949A CN 200680051094 A CN200680051094 A CN 200680051094A CN 101415827 A CN101415827 A CN 101415827A
Authority
CN
China
Prior art keywords
cells
cell
tcr
rna
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2006800510949A
Other languages
English (en)
Chinese (zh)
Inventor
G·舒勒
J·德里
尼尔斯·沙夫特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of CN101415827A publication Critical patent/CN101415827A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K40/4268—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A61K40/4273—Glycoprotein 100 [Gp100]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/89—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microinjection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CNA2006800510949A 2005-12-09 2006-12-11 产生抗原特异性效应t细胞的方法 Pending CN101415827A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05111928.7 2005-12-09
EP05111928A EP1795599A1 (en) 2005-12-09 2005-12-09 Methods for generating antigen-specific effector T cells
US60/779,588 2006-03-06

Publications (1)

Publication Number Publication Date
CN101415827A true CN101415827A (zh) 2009-04-22

Family

ID=36691455

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2006800510949A Pending CN101415827A (zh) 2005-12-09 2006-12-11 产生抗原特异性效应t细胞的方法

Country Status (8)

Country Link
US (1) US20090226404A1 (https=)
EP (2) EP1795599A1 (https=)
JP (1) JP2009518021A (https=)
KR (1) KR20080077272A (https=)
CN (1) CN101415827A (https=)
AU (1) AU2006323961A1 (https=)
CA (1) CA2631785A1 (https=)
WO (1) WO2007065957A2 (https=)

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102574906A (zh) * 2009-07-03 2012-07-11 英美偌科有限公司 T细胞受体
CN102911267A (zh) * 2012-09-19 2013-02-06 南方医科大学 一种结核/hiv抗原肽双特异性tcr、其重组逆转录病毒载体与应用
CN107557339A (zh) * 2017-09-19 2018-01-09 深圳市北科生物科技有限公司 特异性识别plac1的t细胞及其与细胞因子的联合的应用
CN107630005A (zh) * 2017-09-19 2018-01-26 深圳市北科生物科技有限公司 表达plac1特异性tcr的t细胞及其应用
CN108778291A (zh) * 2016-01-06 2018-11-09 健康研究公司 包含重组t细胞受体的组合物和文库以及使用重组t细胞受体的方法
CN108949694A (zh) * 2012-09-11 2018-12-07 康宁有限公司 瞬时过表达编码药物转运蛋白和/或药物代谢酶的基因的可消耗的低温保存的细胞
CN109477073A (zh) * 2016-03-31 2019-03-15 来恩生物医药私人有限公司 表达外源病毒特异性t细胞受体(tcr)的非活化t细胞
CN110200997A (zh) * 2011-03-23 2019-09-06 弗雷德哈钦森癌症研究中心 用于细胞免疫治疗的方法和组合物
CN110627895A (zh) * 2018-06-25 2019-12-31 北京大学 肺癌特异性tcr及其分析技术和应用
WO2020010565A1 (zh) * 2018-07-12 2020-01-16 深圳华大生命科学研究院 Mart-1(27-35)表位特异性t细胞受体
CN110913892A (zh) * 2017-05-02 2020-03-24 免疫治疗有限公司 包含癌抗原的lamp(溶酶体相关膜蛋白)构建物
CN110951690A (zh) * 2010-09-20 2020-04-03 生物技术细胞和基因治疗公司 抗原特异性t细胞受体和t细胞表位
CN112941030A (zh) * 2021-01-25 2021-06-11 吉林大学 一种抗原特异性Treg及其制备方法和应用
CN113185602A (zh) * 2018-04-13 2021-07-30 深圳源正细胞医疗技术有限公司 获得肿瘤特异性t细胞受体的方法
CN117797253A (zh) * 2024-02-29 2024-04-02 诺未科技（北京）有限公司 一种能扩展t细胞抗原表位的肿瘤疫苗及其制备方法

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10112851C1 (de) 2001-03-16 2002-10-10 Gsf Forschungszentrum Umwelt Semi-allogene Antitumor-Vakzine mit HLA-haplo-identischen Antigen-präsentierenden Zellen
US7994298B2 (en) 2004-09-24 2011-08-09 Trustees Of Dartmouth College Chimeric NK receptor and methods for treating cancer
WO2006065495A2 (en) 2004-11-24 2006-06-22 Fred Hutchinson Cancer Research Center Methods of using il-21 for adoptive immunotherapy and identification of tumor antigens
ES2341802T3 (es) * 2005-09-05 2010-06-28 Immatics Biotechnologies Gmbh Peptidos asociados a tumores unidos promiscuamente a moleculas del antigeno de leucocito humano (hla) de clase ii.
EP2126054B1 (en) 2007-01-31 2016-07-06 Yeda Research And Development Company Limited Redirected, genetically-engineered t regulatory cells and their use in suppression of autoimmune and inflammatory disease
US9249423B2 (en) 2007-02-02 2016-02-02 Yale University Method of de-differentiating and re-differentiating somatic cells using RNA
US8859229B2 (en) * 2007-02-02 2014-10-14 Yale University Transient transfection with RNA
US10155038B2 (en) 2007-02-02 2018-12-18 Yale University Cells prepared by transient transfection and methods of use thereof
GB0718160D0 (en) 2007-09-18 2007-10-24 Medical Res Council Methods
US9809797B2 (en) 2007-10-03 2017-11-07 National Institutes Of Health (Nih) U.S. Dept. Of Health And Human Services (Dhhs) Division Of Extramural Inventions And Technology Enhanced generation of cytotoxic T-lymphocytes by IL-21 mediated FOXP3 suppression
KR100900837B1 (ko) 2007-12-07 2009-06-04 (주)두비엘 리포펩타이드와 폴리(ｉ:ｃ)를 아쥬반트로 포함하는 강력한백신 조성물
EP2090659A1 (en) * 2008-02-14 2009-08-19 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Infectious particle, process for its preparation and use thereof
WO2009108341A1 (en) 2008-02-28 2009-09-03 Argos Therapeutics, Inc. Transient expression of immunomodulatory polypeptides for the prevention and treatment of autoimmune disease, allergy and transplant rejection
US8450112B2 (en) 2008-04-09 2013-05-28 Maxcyte, Inc. Engineering and delivery of therapeutic compositions of freshly isolated cells
US20140161782A1 (en) * 2008-06-09 2014-06-12 Targazyme, Inc. Augmentation of cell therapy efficacy including treatment with alpha 1-3 fucoslytransferase
CN102272153B (zh) 2008-11-24 2015-04-15 德国慕尼黑亥姆霍兹研究中心健康和环境有限公司 高亲和力t细胞受体及其应用
WO2010089412A1 (en) 2009-02-09 2010-08-12 Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Fuer Gesundheit Und Umwelt (Gmbh) Repertoire of allo-restricted peptide-specific t cell receptor sequences and use thereof
US12492376B2 (en) 2009-10-29 2025-12-09 The Trustees Of Dartmouth College T-cell receptor-deficient T cell compositions
WO2011059836A2 (en) 2009-10-29 2011-05-19 Trustees Of Dartmouth College T cell receptor-deficient t cell compositions
US9273283B2 (en) 2009-10-29 2016-03-01 The Trustees Of Dartmouth College Method of producing T cell receptor-deficient T cells expressing a chimeric receptor
US9833476B2 (en) 2011-08-31 2017-12-05 The Trustees Of Dartmouth College NKP30 receptor targeted therapeutics
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
AU2013243948A1 (en) 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins associated with human disease
US10501513B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides for the production of oncology-related proteins and peptides
ES2719495T5 (en) 2012-05-07 2025-09-10 Dartmouth College Anti-b7-h6 antibody, fusion proteins, and methods of using the same
JP6580579B2 (ja) 2014-01-29 2019-09-25 ユニバーシティー ヘルス ネットワーク Ｔ細胞受容体を発現する細胞を生産する方法および組成物
WO2016095934A2 (en) * 2014-12-14 2016-06-23 El Abd Hisham Mohamed Magdy A novel genetic device to engineer cell behavior
ES2857998T3 (es) 2015-02-12 2021-09-29 Univ Health Network Receptores de antígenos quiméricos
JP6952225B2 (ja) * 2016-03-18 2021-10-20 北海道公立大学法人 札幌医科大学 Ｔ細胞レセプターとその利用
WO2017208018A1 (en) 2016-06-02 2017-12-07 Immunocore Limited Dosing regimen for gp100-specific tcr - anti-cd3 scfv fusion protein
CA3076261A1 (en) 2017-09-19 2019-03-28 Admare Vintageco1 Investments Ltd. Anti-hla-a2 antibodies and methods of using the same
EP3684822A4 (en) 2017-09-20 2021-06-16 The University of British Columbia NEW ANTI-HLA-A2 ANTIBODIES AND USES THEREOF
WO2019241549A1 (en) 2018-06-15 2019-12-19 A2 Biotherapeutics, Inc. Foxp3-expressing car-t regulatory cells
US20220370586A1 (en) * 2019-08-08 2022-11-24 Cedars-Sinai Medical Center Method of generating activated t cells for cancer therapy
US12378521B2 (en) 2020-04-15 2025-08-05 Amgen Inc. Method for enhancing production of genetically engineered autologous T cells
US12241086B2 (en) 2020-04-15 2025-03-04 Amgen Inc. Process for generating genetically engineered autologous T cells
CA3218590A1 (en) 2021-06-07 2022-12-15 Providence Health & Services - Oregon Cxcr5, pd-1, and icos expressing tumor reactive cd4 t cells and their use
WO2024008274A1 (en) * 2022-07-04 2024-01-11 Universiteit Antwerpen T regulatory cell modification

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8211422B2 (en) * 1992-03-18 2012-07-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric receptor genes and cells transformed therewith
EP1188825A1 (en) * 2000-09-18 2002-03-20 Universiteit Leiden T cell receptor transfer into a candidate effector cell or a precursor thereof
US7723111B2 (en) * 2001-03-09 2010-05-25 The United States Of America As Represented By The Department Of Health And Human Services Activated dual specificity lymphocytes and their methods of use
GB0111015D0 (en) * 2001-05-04 2001-06-27 Norsk Hydro As Genetic material
KR20060126516A (ko) * 2003-11-25 2006-12-07 아르고스 쎄라퓨틱스 인코포레이티드 Ｍｒｎａ로 전달이입된 항원제시세포

Cited By (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102574906A (zh) * 2009-07-03 2012-07-11 英美偌科有限公司 T细胞受体
CN104017067A (zh) * 2009-07-03 2014-09-03 英美偌科有限公司 T细胞受体
CN110951690A (zh) * 2010-09-20 2020-04-03 生物技术细胞和基因治疗公司 抗原特异性t细胞受体和t细胞表位
CN110200997A (zh) * 2011-03-23 2019-09-06 弗雷德哈钦森癌症研究中心 用于细胞免疫治疗的方法和组合物
CN108949694A (zh) * 2012-09-11 2018-12-07 康宁有限公司 瞬时过表达编码药物转运蛋白和/或药物代谢酶的基因的可消耗的低温保存的细胞
CN108949694B (zh) * 2012-09-11 2022-06-17 康宁有限公司 瞬时过表达编码药物转运蛋白和/或药物代谢酶的基因的可消耗的低温保存的细胞
CN102911267A (zh) * 2012-09-19 2013-02-06 南方医科大学 一种结核/hiv抗原肽双特异性tcr、其重组逆转录病毒载体与应用
CN108778291B (zh) * 2016-01-06 2020-11-10 健康研究公司 包含重组t细胞受体的组合物和文库以及使用重组t细胞受体的方法
CN108778291A (zh) * 2016-01-06 2018-11-09 健康研究公司 包含重组t细胞受体的组合物和文库以及使用重组t细胞受体的方法
US11020431B2 (en) 2016-01-06 2021-06-01 Health Research, Inc. Compositions and libraries comprising recombinant T-cell receptors and methods of using recombinant T-cell receptors
CN109477073A (zh) * 2016-03-31 2019-03-15 来恩生物医药私人有限公司 表达外源病毒特异性t细胞受体(tcr)的非活化t细胞
CN109477073B (zh) * 2016-03-31 2024-04-12 来恩生物医药私人有限公司 表达外源病毒特异性t细胞受体(tcr)的非活化t细胞
CN110913892A (zh) * 2017-05-02 2020-03-24 免疫治疗有限公司 包含癌抗原的lamp(溶酶体相关膜蛋白)构建物
CN107630005A (zh) * 2017-09-19 2018-01-26 深圳市北科生物科技有限公司 表达plac1特异性tcr的t细胞及其应用
CN107557339A (zh) * 2017-09-19 2018-01-09 深圳市北科生物科技有限公司 特异性识别plac1的t细胞及其与细胞因子的联合的应用
CN113185602A (zh) * 2018-04-13 2021-07-30 深圳源正细胞医疗技术有限公司 获得肿瘤特异性t细胞受体的方法
CN113185602B (zh) * 2018-04-13 2023-03-10 深圳源正细胞医疗技术有限公司 获得肿瘤特异性t细胞受体的方法
CN110627895B (zh) * 2018-06-25 2021-03-23 北京大学 肺癌特异性tcr及其分析技术和应用
CN110627895A (zh) * 2018-06-25 2019-12-31 北京大学 肺癌特异性tcr及其分析技术和应用
CN112469733B (zh) * 2018-07-12 2022-04-19 深圳华大生命科学研究院 Mart-1(27-35)表位特异性t细胞受体
CN112469733A (zh) * 2018-07-12 2021-03-09 深圳华大生命科学研究院 Mart-1(27-35)表位特异性t细胞受体
WO2020010565A1 (zh) * 2018-07-12 2020-01-16 深圳华大生命科学研究院 Mart-1(27-35)表位特异性t细胞受体
US12134637B2 (en) 2018-07-12 2024-11-05 Bgi Shenzhen MART-1(27-35) epitope-specific T cell receptor
CN112941030A (zh) * 2021-01-25 2021-06-11 吉林大学 一种抗原特异性Treg及其制备方法和应用
CN112941030B (zh) * 2021-01-25 2023-08-08 吉林大学 一种抗原特异性Treg及其制备方法和应用
CN117797253A (zh) * 2024-02-29 2024-04-02 诺未科技（北京）有限公司 一种能扩展t细胞抗原表位的肿瘤疫苗及其制备方法

Also Published As

Publication number Publication date
WO2007065957A3 (en) 2007-07-26
CA2631785A1 (en) 2007-06-14
US20090226404A1 (en) 2009-09-10
EP1795599A1 (en) 2007-06-13
WO2007065957A2 (en) 2007-06-14
AU2006323961A1 (en) 2007-06-14
KR20080077272A (ko) 2008-08-21
JP2009518021A (ja) 2009-05-07
EP1960527A2 (en) 2008-08-27

Similar Documents

Publication Publication Date Title
CN101415827A (zh) 产生抗原特异性效应t细胞的方法
CN113631172B (zh) 用于靶向突变型ras的组合物和方法
US20230287347A1 (en) Exosome for stimulating t cell and pharmaceutical use thereof
Schaft et al. A new way to generate cytolytic tumor-specific T cells: electroporation of RNA coding for a T cell receptor into T lymphocytes
JP6230208B2 (ja) 樹状細胞／腫瘍細胞融合物および抗ｃｄ３／ｃｄ２８を使用する抗腫瘍免疫の刺激
JP2022065022A (ja) 改変ヒト初代血液樹状細胞株を生成するための方法
JP2011504101A5 (https=)
CA2940163C (en) Tscm cells and methods for use
Erdmann et al. Effective clinical-scale production of dendritic cell vaccines by monocyte elutriation directly in medium, subsequent culture in bags and final antigen loading using peptides or RNA transfection
JP2018506287A (ja) Ｈｅｒ２／Ｎｅｕ （ＥＲＢＢ２）受容体タンパク質に由来する３６９〜３７７位エピトープに特異的な完全ヒトＴ細胞受容体
Toujas et al. Human monocyte‐derived macrophages and dendritic cells are comparably effective in vitro in presenting HLA class I‐restricted exogenous peptides
WO2009149539A1 (en) Enhancing antigen-specific cd8+ t cell response using irf-7 mrna
US20210317410A1 (en) Methods of making natural killer cells and uses thereof
KR102030364B1 (ko) 멀티플렉스 CRISPR-Cas9 시스템을 이용한 HLA 결핍 세포주로부터 제조된 인공항원제시세포 및 이의 용도
JP5054875B2 (ja) 樹状細胞ハイブリッドによって活性化される細胞傷害性ｔリンパ球
KR20080106193A (ko) 막 귀소 폴리펩티드로 일시적 형질이입된 가지 세포 및 그의 용도
HK1128489A (en) Methods for generating antigen-specific effector t cells
Tapirdamaz et al. A new approach for quantification of T-cells with indirect alloreactivity
NZ735850A (en) Claudin-18.2-specific immunoreceptors and t cell epitopes
NZ723544A (en) Claudin-6-specific immunoreceptors and t cell epitopes
CN101600445A (zh) 膜归巢多肽瞬时转染的树突细胞及它们的应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1128489

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20090422

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1128489

Country of ref document: HK